Industry Funding Opportunities

For all InPart Funding Listings please Contact Karla Zepeda

BASF - Biodegradable Micro-Encapsulation of Agricultural Ingredients

InPart Funding
Chemical

Deadline: 5th July 2022 - 10:59 pm GMT BASF is an industry leading chemicals company creating solutions for a sustainable future. The company is seeking biodegradable micro-encapsulation technologies for agricultural active ingredients. BASF is particularly interested in non-microplastic core/ shell particles to encapsulate hydrophobic active ingredients. Approaches of Interest Biodegradable encapsulation materials for hydrophobic active ingredients Polymers from natural sources/ resources are preferred Capsule sizes should ideally be d(50) < ~ 5 μm and d(90) < ~15 μm Core/ shell morphologies are of high interest but relevant matrix capsules and other morphologies will be considered The active ingredient concentration to be encapsulated is >10% A >90% encapsulation efficiency is ideal Goods should be cost-effective and ideally <~20 $/kg for the capsule material and < ~2 $/kg for manufacturing Measurement of biodegradability should follow ISO 17556:2012: 90% ultimate degradation in soil at 12 °C within 24 months Applicable encapsulation technologies developed for other applications are also of interest

Open BASF - Biodegradable Micro-Encapsulation of Agricultural Ingredients PDF

RHI Magnesita GmBH - Processes of Green Carbon Removal from Refractories for Recycling

InPart Funding
Therapeutics and Vaccines

Deadline: May 3rd 2022 Carbon bonded bricks are widely used refractory bricks in the steel industry. They are produced from burned, inorganic raw materials, graphite, and binders (pitch or PF resin) via a tempering process. For recycling, tempered bricks (carbon containing) have a higher availability than fired bricks of a similar chemical composition and the presence of carbon limits its reintroduction into the production chain. RHI Magnesita GmbH, a global leader in the refractory industry, is looking to develop or match a green process to convert carbon bonded secondary refractory raw materials into usable materials. Submission Information Submission of one page, 200-300 word briefs are encouraged, along with any optional supplementary information e.g., relevant publications and patents. In submitting to this campaign, you confirm that your submission contains only nonconfidential information. Opportunity for Collaboration RHI Magnesita GmbH is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licencing assets, research collaborations, and project/PhD funding.

Open RHI Magnesita GmBH - Processes of Green Carbon Removal from Refractories for Recycling PDF

Xencor - Seeking Novel Anti-tumour Antibodies

InPart Funding
Therapeutics and Vaccines

Deadline: June 6th 2022 Xencor is a clinical-stage biopharmaceutical company focused on the discovery and development of bispecific antibodies and cytokine drugs. Xencor is currently seeking monoclonal antibodies directed against tumour-associated antigens, for incorporation into their clinically validated T cell engager platform. Submission Information Submission of one page, 200-300 word briefs are encouraged. Along with any optional supplementary information e.g. relevant publications and patents. In submitting to this campaign, you confirm that your submission contains only nonconfidential information. Opportunity for Collaboration Xencor is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, research collaborations and sponsored research opportunities

Open Xencor - Seeking Novel Anti-tumour Antibodies PDF

Anonymous - Novel Approaches to DNA and RNA Synthesis

InPart Funding
Therapeutics and Vaccines

Deadline: May 30th 2022 A global life sciences measurement and tools company with cutting-edge capabilities in genomic analysis and quality assurance wishes to identify novel approaches for scalable synthesis of oligonucleotides. Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-bycase basis. Example outcomes include licensing assets, research collaborations, and project/PhD/Post‑Doc funding.

Open Anonymous - Novel Approaches to DNA and RNA Synthesis PDF

Healx - Seeking Opportunities for the Treatment of Rare or Orphan Diseases

InPart Funding
Therapeutics and Vaccines

Deadline: June 6th 2022 Healx, an AI-powered, patient-inspired, biotech company, is seeking rare disease therapeutic opportunities from academic, patient groups or (early-stage) biotechs. Healx, along with their partners, aim to quickly turn research into treatments that benefit the rare disease community, and Healx will manage the costs of clinical trials and regulatory submissions for all selected opportunities (subject to final deal terms). Opportunity for Collaboration and Submission Information Healx is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a caseby- case basis. Example outcomes include in‑licensing clinic‑ready assets for clinical development, option agreements with research funding and co‑development for preclinical assets To submit your research, please fill in the submission form . In submitting to this campaign, you confirm that your submission contains only non‑confidential information

Open Healx - Seeking Opportunities for the Treatment of Rare or Orphan Diseases PDF

Chiesi Global - Technologies to Address Distribution of Macromolecules in Hard-to-reach Tissues

InPart Funding
Therapeutics and Vaccines

Deadline: May 30th 2022 Chiesi Global Rare Diseases is seeking research proposals for new technologies from academic  medical centres, universities, and research institutions globally. Their objective is to award  funds to validate early‑stage projects with clear therapeutic potential. Successful applicants will  be funded through sponsored research, with up to $275K/€250K available per project for 2 years  duration. This should enable researchers to generate relevant preclinical data or demonstrate preclinical  proof of concept for technologies enabling effective biodistribution of macromolecules (for example: nucleic acids, proteins) to the following tissues of interest,  characterised by challenges in delivery (any or all): Bone Skeletal/cardiac muscle Central nervous system for the treatment of rare metabolic disorders, for example inborn errors of metabolism, including  lysosomal storage disorders. The technology might be brought into the Chiesi Global Rare Diseases pipeline and ultimately benefit  patients. Submission Information The first step in the process is submission of a Pre‑Proposal which should contain a brief, non‑confidential 2‑3 page overview of the target, mechanism (including evidence for link to disease), and the proposed therapeutic opportunity. To submit your proposal, please visit our website at discover.in-part.com , register, and submit your research pre‑proposal under the appropriate Discover campaign. A more detailed Full Proposal will be solicited by invitation only.  

Open Chiesi Global - Technologies to Address Distribution of Macromolecules in Hard-to-reach Tissues PDF

BioMarin Pharmaceuticals - Research Opportunities for C-type Natriuretic Peptide

InPart Funding
Therapeutics and Vaccines

Deadline: May 3rd 2022 Submission Information Submission of either this optional submission form or alternatively one page, 200‑300 words briefs are encouraged, along with any optional supplementary information (e.g., relevant publications, patents, slide decks) In submitting to this campaign, you confirm that your submission contains only non‑confidential information Opportunity for Collaboration BioMarin Pharmaceutical Inc. is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis.

Open BioMarin Pharmaceuticals - Research Opportunities for C-type Natriuretic Peptide PDF

Anonymous - Generation of iPSC-derived T Cells for Therapeutic Use

InPart Funding
Therapeutics and Vaccines

Deadline: May 9th 2022  Approaches of Interest Differentiation of iPSCs into haematopoietic stem and progenitor cells (HSPC) in feeder cell-free systems Differentiation of iPSC-derived HSPC into T cells in feeder cell-free system with improvements to shortening the differentiation cycle Expansion of iPSC-derived T cells in feeder cell-free system Approaches to increase the lymphoid potential of iPSC-derived cells, e.g. pathways, genetic modifications, transcription factors, reagents or culture conditions Insights into T cell receptor gene (TCR) rearrangement and strategies to prevent or monitor TCR rearrangement Approaches to improve the functional attributes (e.g. cytokine secretion) of iPSC-derived T cells, e.g. pathways, genetic modifications, transcription factors, reagents or culture conditions All improvement to the above processes where there are promising good manufacturing practice methods, scalable processes and technologies to advance the allogeneic platform Applications in oncology are of interest Out of Scope Natural Killer cell focused research is of lesser interest, although intermediate NKTs are within scope Stage of Development Opportunities from basic through to clinical phase I are within scope Submission Information Submission of one page, 200-300 word briefs are encouraged. In submitting to this campaign, you confirm that your submission contains only non-confidential information Potential Collaborations for Academics Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licencing and research collaborations

Open Anonymous - Generation of iPSC-derived T Cells for Therapeutic Use PDF